- BMY maintained its quarterly dividend at $0.63 per share, supporting a 3.77% forward yield at the latest quoted price.
- Levered free cash flow and net income exceed the annual dividend obligation, though debt remains a key risk.
- New growth products accounted for about 56% of first-half 2026 revenue as Bristol Myers Squibb faces pressure on older medicines.
BMY dividends remain steady ahead of October 2 ex-dividend date
Bristol Myers Squibb reaffirmed its $0.63 quarterly dividend, or $2.52 per share annually. At the latest quoted price of $66.82, the BMY dividend produces a 3.77% forward yield, below the roughly 4% yield available when shares traded near $62 earlier this month.
The next ex-dividend date is October 2, 2026. Investors must own the shares before that date to receive the upcoming payment, although buying solely to capture a dividend is rarely a winning strategy because the share price generally adjusts lower by approximately the dividend amount on the ex-dividend date.
BMY dividends have increased at a measured pace, with growth averaging 2.0% over one year and 5.5% over five years. That profile suits investors seeking current income with moderate growth potential rather than rapid dividend compounding.
Cash flow supports the Bristol Myers Squibb dividend
Bristol Myers generated $8.11 billion in levered free cash flow and $9.28 billion in trailing net income, comfortably exceeding its annual dividend obligation. Its current ratio of 1.53 also points to adequate near-term liquidity.
Leverage remains a key caveat. The company carries roughly $42.1 billion in long-term debt against $11.5 billion in cash, requiring management to balance dividends, debt reduction, acquisitions and pipeline investment carefully.
For now, the unchanged BMY dividend signals stability, not a new acceleration in shareholder returns.
Low BMY valuation reflects revenue concerns
At about 14.7 times trailing earnings, BMY trades at a discount to many large pharmaceutical peers. On forward estimates, it is valued at about 9.6 times earnings, reflecting investor concern over future revenue erosion.
The shares are near the upper end of their $42.52 to $68.64 52-week range. A consensus price target of $66.71 suggests limited near-term upside from the latest price, although a bullish $82 target illustrates the potential if execution improves.
New medicines face the test of replacing legacy sales
Growth products, including Cobenfy, Camzyos, Reblozyl, Breyanzi and Opdivo Qvantig, represented about 56% of first-half 2026 revenue. Eliquis and Opdivo eventually face exclusivity and competitive pressures, while older products such as Revlimid continue to decline.
Dividend investors should watch the October 29 earnings release for new-product sales growth, free-cash-flow conversion, debt reduction and changes to management’s capital-return priorities. BMY remains a credible higher-income pharmaceutical stock for investors comfortable with turnaround risk, but the long-term appeal of BMY dividends rests on whether new launches can offset the looming patent cliff.
